Clinical trial yields fewer relapses in multiple sclerosis patients treated with off-label drug
Experts rue simple steps not taken before latest COVID surge
13 July 2022Hidden consciousness detected with EEG predicts recovery of unresponsive patients
13 July 2022Clinical trial yields fewer relapses in multiple sclerosis patients treated with off-label drug
Patients with multiple sclerosis (MS) treated with the drug rituximab had a significantly lower risk of relapse compared with MS patients receiving standard treatment. This has been shown in a phase 3 clinical trial by researchers at Karolinska Institutet and Danderyd Hospital in Sweden published in The Lancet Neurology. Rituximab is not approved as an MS drug, but has proven to be effective in smaller studies and is therefore largely prescribed “off label.”
